2025 Market SizeUSD 1.24 BnBase year
2026 EstimateUSD 1.39 BnEstimated year
2034 ForecastUSD 3.54 BnForecast value
CAGR12.4%2026–2034
Largest RegionNorth America2025
Cancer Stem Cell Therapy Market Overview
The global Cancer Stem Cell Therapy Market was valued at USD 1.24 billion in 2025, is estimated at USD 1.39 billion in 2026, and is projected to reach USD 3.54 billion by 2034, reflecting a 12.4% CAGR during 2026–2034.
20.6MNew cancer diagnoses globally in 2024IARC, July 2026
47,204Hematopoietic cell transplants reported to EBMT for 2024EBMT, May 2026
22,000+U.S. marrow and cord blood transplants in 2024HRSA
12 daysMedian neutrophil recovery with OmisirgeFDA, April 2023
Cancer stem cells are self-renewing tumour subpopulations associated with recurrence, therapy resistance and metastatic potential. Established oncology use of blood-forming stem cells is different: transplantation restores haematopoiesis after high-dose cancer treatment rather than directly eliminating cancer stem cells. Commercial activity covered here includes oncology-related transplant procedures, collection and conditioning support, cell-processing products, and discovery services pursuing cancer-stem-cell targets. Investigational CSC-targeted medicines are not described as approved treatments, and transplant-related revenue is not the same as sales of a CSC-specific drug.
The International Agency for Research on Cancer estimated 20.6 million new cancers in 2024 and 9.8 million deaths. Haematological malignancies remain the principal established setting for transplant-associated spending. The EBMT reported 47,204 haematopoietic cell transplants in 2024, including 26,181 autologous and 21,023 allogeneic procedures. Such clinical volume supports demand for cell mobilization, apheresis, donor matching, processing consumables and inpatient care, while the size of direct CSC-targeted drug sales remains limited by clinical development.
The FDA approved Omisirge in April 2023 to accelerate neutrophil recovery following cord-blood transplantation for eligible blood-cancer patients. In a randomized study, median neutrophil recovery was 12 days with Omisirge versus 22 days with standard cord blood. In September 2023, FDA approval of Aphexda added a stem-cell mobilization option for multiple myeloma. These approvals expand transplant-associated treatment options without proving a separate class of approved medicines that eradicate tumour-initiating cancer stem cells.
Cancer-stem-cell research is testing Wnt, Notch, Hedgehog, metabolic and immune mechanisms, but clinical evidence is heterogeneous and many approaches remain early-stage. Separately, equipment and consumables from Terumo BCT, Fresenius Kabi, Miltenyi Biotec and specialized culture suppliers support established transplant workflows and investigational studies. Hospitals account for most procedure-linked expenditure, while oncology laboratories and biopharmaceutical developers create smaller technology and clinical-stage revenue streams. NHS-defined eligibility and documented graft complications can restrict demand even at established transplant hospitals.
Source: IARC Global Cancer Statistics 2024; EBMT 2024 activity report; FDA Omisirge approval; NCI transplant explanation.
Key Takeaways: Cancer Stem Cell Therapy Market
- Base-year market size: Global oncology-related stem-cell therapy and associated research revenue reached an estimated USD 1.24 billion in 2025 within the defined boundary.
- Forecast and CAGR: The modeled market reaches USD 3.54 billion by 2034, equivalent to 12.4% annual growth from its 2026 baseline.
- Leading type: Autologous Stem Cell Transplants represented an estimated ~53% of 2025 revenue, reflecting the volume of multiple-myeloma and lymphoma procedures.
- Leading application: Hospital represented an estimated ~73% of 2025 revenue, supported by inpatient transplantation and accredited cell-processing centres.
- Largest region: North America accounted for an estimated ~42% of 2025 revenue, reflecting high procedure intensity and cell-therapy infrastructure.
- Key drivers: Increasing transplant access, FDA-cleared collection and cord-blood products, greater cancer incidence and clinical investment in CSC biology support demand.
- Competitive landscape: Gamida Cell, BioLineRx, Mesoblast, Sanofi and suppliers of mobilization, apheresis and cell-processing technologies serve different steps of the value chain.
- Report coverage: Forecasts cover transplant Type, Application, End User and Therapeutic Target in five world regions, including investigational CSC-targeting approaches.
Report Scope & Market Segmentation
The analysis includes cancer-related haematopoietic stem-cell transplant activity and associated drugs, processing equipment and qualified research services while distinguishing them from investigational treatments intended to eliminate tumour-initiating cells.
| Report Attribute |
Coverage |
| Base Year |
2025 |
| Estimated Year |
2026 |
| Forecast Period |
2026–2034 |
| Market Measurement |
Revenue, USD million/billion |
| By Type |
Autologous Stem Cell Transplants; Allogeneic Stem Cell Transplants; Syngeneic Stem Cell Transplants; Others |
| By Application |
Hospital; Clinic; Medical Research Institution; Others |
| By End User |
Healthcare Providers; Academic & Research Institutes; Pharmaceutical & Biotechnology Companies |
| By Therapeutic Target |
Solid Tumors; Hematological Cancers; Other Cancers |
| By Region |
North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries |
United States; Canada; United Kingdom; Germany; China; Japan; India; Brazil; Saudi Arabia; United Arab Emirates |
| Key Market Players |
Gamida Cell Ltd.; BioLineRx Ltd.; Mesoblast Limited; Sanofi S.A.; Fresenius Kabi AG; Terumo Blood and Cell Technologies; Miltenyi Biotec; Thermo Fisher Scientific Inc.; Bio-Techne Corporation; STEMCELL Technologies Inc.; Lonza Group AG |
Market Definition & Revenue Boundaries
Cancer stem cells (CSCs) are tumor cells with stem-like self-renewal properties, whereas haematopoietic stem cells (HSCs) are normal progenitor cells used to reconstitute blood formation. Autologous, allogeneic and syngeneic transplantation is established in selected blood cancers but is not an approved CSC-specific eradication strategy. This revenue boundary includes oncology-associated transplant services and dedicated mobilization, graft manipulation and processing supply, plus directly relevant research and clinical-stage contracted activity. It excludes total oncology drug sales, all CAR-T sales, unrelated regenerative indications and general laboratory or equipment revenue.
Publisher categories are maintained but interpreted without claiming therapeutic equivalence: Others under Type represents oncology-related cord-blood graft processing and investigational CSC-directed delivery services outside the three donor relationships. Hospital and Healthcare Providers overlap conceptually but are independent classifications, not revenues to add together; Application classifies the delivery location while End User describes the purchaser. All estimated segment shares describe the same defined revenue pool and total 100% within each dimension.
Cancer Stem Cell Therapy Market Dynamics
Rising treatment demand supports transplant-centre utilization
IARC recorded 20.6 million new cancer diagnoses in 2024, a burden that increases the need for oncology treatment services without implying that all cancers need transplantation. NCI identifies leukaemia, lymphoma and multiple myeloma as principal stem-cell transplant indications. The U.S. HRSA reports more than 22,000 marrow and cord-blood transplants in 2024, with autologous and allogeneic routes requiring different collection, inpatient and follow-up resources. Higher utilization creates demand for apheresis disposables, specialized culture media, infectious-disease testing and donor-search services, although eligibility and competing treatment options govern actual procedures.
Regulatory approvals improve the clinical transplant pathway
The FDA approved Gamida Cell Omisirge in April 2023 for certain patients with blood cancers undergoing cord-blood transplantation, based on faster immune-cell recovery and fewer infections. BioLineRx Aphexda was approved in September 2023 for autologous stem-cell mobilization in multiple myeloma, adding an alternative in an established transplant workflow. Both products target specific procedure needs rather than demonstrating eradication of self-renewing cancer cells. Commercial uptake therefore depends on transplant referrals, clinical guidelines, reimbursement and hospital formulary adoption, creating a narrower but identifiable revenue channel than general oncology biologics.
Tumour heterogeneity complicates CSC-specific development
A 2025 peer-reviewed review of cancer stem cells documents multiple self-renewal networks including Wnt, Notch, Hedgehog and PI3K/AKT/mTOR. Tumours often contain shifting cell states, so inhibition of a single pathway may spare resistant populations. Stemness markers such as CD44 and CD133 can also appear on normal cells, complicating safety and target validation. These biological constraints lengthen drug development and increase assay, organoid and multi-omic profiling requirements. Research-services revenue may expand even when clinical-stage CSC-targeting assets fail to reach marketing authorization or generate therapeutic sales.
Complications and collection logistics restrain access
NCI states that allogeneic transplantation requires sufficient donor compatibility and can cause graft-versus-host disease, while autologous transplantation involves a risk of reinfusing malignant cells. Immune recovery may take one to two years after allogeneic or syngeneic procedures. Hospitals must therefore budget isolation facilities, infection monitoring, laboratory testing and long-term surveillance in addition to the graft itself. High-acuity resource requirements restrict access to specialist centres and can deter payers from expanding low-evidence indications, especially where treatment-related mortality competes with newer targeted and immune therapies.
Donor availability and reimbursement shape geographic demand
Canadian Blood Services operates a stem-cell donor registry linked to international matching systems, while NHS England commissions haematopoietic stem-cell transplantation only for specified clinical subgroups. EBMT reported 21,023 allogeneic transplants during 2024 across its participating centres, highlighting the importance of donor access and institutional capacity. Better matching can broaden eligibility, but donor search, collection, shipping and follow-up remain resource intensive. Procurement of cell-processing products benefits from stable transplant programmes, whereas reimbursed growth depends on government criteria and insurers rather than laboratory innovation alone.
Sources: IARC; NCI; HRSA; FDA Omisirge and Aphexda approvals; EBMT; Canadian Blood Services; NHS England; 2025 cancer-stem-cell review.
Market Trends & Growth Opportunities
Cord-blood engineering shortens post-transplant recovery
FDA approval of Omisirge in April 2023 followed randomized evidence of median neutrophil recovery in 12 days versus 22 days using conventional cord blood. Gamida Cell uses ex vivo expansion of donor cord blood cells to support immune reconstitution after myeloablative conditioning in hematological malignancies. Faster recovery can reduce the window of infection vulnerability and may alter resource consumption per transplant. The commercial benefit remains restricted to patients meeting the approved indication, while separate investigational efforts to attack cancer stem cells need their own efficacy and safety trials.
New mobilization products alter collection economics
In September 2023, FDA approved Aphexda with filgrastim for stem-cell mobilization before autologous transplantation in multiple myeloma. The GENESIS study enrolled 122 patients across the United States and four European countries. Collection efficiency affects the number of apheresis sessions and scheduling pressure at transplant centres. BioLineRx competes with established plerixafor pathways, including Mozobil, while Fresenius Kabi and Terumo BCT supply equipment used for mononuclear cell harvesting. Payers may evaluate cost per successful collection rather than drug acquisition price alone.
Registry monitoring makes indications and geographic gaps measurable
The EBMT 2024 activity survey reported 47,204 haematopoietic cell transplants in 53 participating countries and 6,082 CAR-T recipients, showing distinct procedural categories in contemporary registries. China reported 21,714 HSC transplants during 2023 in its national registry, while Japan publishes annual national transplantation and cellular-therapy counts. Registry-driven treatment tracking helps centres compare donor types, complications and eligible populations. Better data quality can improve procurement planning, but transplant volumes cannot be directly converted into CSC-targeted pharmaceutical sales without an explicit revenue attribution.
Tumour organoids support biomarker-directed screening
A 2024 review identifies CD44, CD133, aldehyde dehydrogenases and Wnt/Notch signalling among candidate markers and pathways for CSC research. STEMCELL Technologies sells IntestiCult media for colorectal cancer organoids and MammoCult products for mammosphere or tumoursphere culture. Bio-Techne offers cell-culture media for CD34-positive haematopoietic progenitors, providing a different cell-biology workflow. Researchers use these platforms to test drug response and cell-state heterogeneity before human trials. Research product demand need not correlate directly with successful regulatory approval of a cancer-stem-cell-selective therapy.
Manufacturing services bridge research and clinical supply
Lonza reported in its 2025 annual report that its cell-and-gene therapy sites had commercial manufacturing contracts, while Miltenyi Biotec describes closed-system CliniMACS workflows for CD34-positive cell engineering. Thermo Fisher supplies CTS StemPro media for expanding HSCs obtained from cord blood, marrow and mobilized peripheral blood. Controlled manufacturing and batch traceability raise costs for both clinical trials and commercial graft products. Capital spending is more defensible when tied to validated transplant or cell-therapy programmes than to assumptions about rapid authorization of experimental CSC-directed agents.
Transplantation & CSC-Targeted Therapeutic Landscape
Autologous and allogeneic haematopoietic stem-cell transplantation are clinically established for selected blood cancers, whereas drug strategies intended to selectively eliminate tumour-initiating cancer stem cells remain under investigation. The distinction affects clinical claims, reimbursement and the type of revenue counted across the supply chain.
| Intervention |
Evidence or Status |
Measured Finding |
Market Relevance |
| Autologous HSC transplant |
EBMT activity survey, 2024 |
26,181 procedures |
Patient-derived graft collection and processing |
| Allogeneic HSC transplant |
EBMT activity survey, 2024 |
21,023 procedures |
Donor matching, immune recovery and GVHD monitoring |
| Omisirge, cord blood graft |
FDA approval, April 2023 |
12 versus 22 days median neutrophil recovery |
Expanded-cord-blood product for eligible blood cancers |
| Aphexda with G-CSF |
FDA approval, September 2023 |
GENESIS trial enrolled 122 patients |
Mobilization before autologous myeloma transplant |
| CSC signalling inhibitors |
2025 peer-reviewed CSC review |
Clinical benefit remains heterogeneous |
Investigational development and assay demand |
NCI explains that normal donor or patient stem cells rebuild blood-cell production following high-dose chemotherapy or radiation; transplantation should not be characterized as direct destruction of cancer stem cells. EBMT recorded 26,181 autologous procedures and 21,023 allogeneic procedures in 2024. Autologous routes avoid donor graft-versus-host reactions, whereas allogeneic grafts may generate graft-versus-tumour immunity but carry greater compatibility and immune complications. These distinctions change resource consumption, clinical eligibility and procurement of cell collection and handling products.
In a controlled study leading to FDA approval, Omisirge recipients had median neutrophil recovery in 12 days against 22 days for conventional cord blood, with fewer serious infections by day 100. APHEXDA offers a separate option for collecting sufficient autologous stem cells in multiple myeloma; neither product has an indication to selectively kill CSCs. In December 2024, FDA also approved Mesoblast Ryoncil for pediatric steroid-refractory graft-versus-host disease, an adverse transplant complication rather than a treatment of cancer itself.
The 2025 cancer-stem-cell review reports continued study of pathway blockade, immune combinations and metabolic vulnerabilities, with resistance, toxicity and intratumoral heterogeneity limiting translation. Clinical-stage costs arise from model development, marker validation, GMP production and trial execution before any cancer-specific authorization. Commercial transplant services already have reimbursed clinical indications, while experimental CSC elimination may generate research or licensed-development revenue without reaching general treatment availability. Clinical trial setbacks in CSC pathways do not remove the established need for haematopoietic graft collection.
Cancer Stem Cell Therapy Market Segmentation by Type
Report SegmentationBy Type
Autologous Stem Cell Transplants represented an estimated ~53% of 2025 revenue across the defined oncology transplant and CSC-research activities. EBMT counted more autologous than allogeneic HCT procedures in 2024, and U.S. HRSA statistics similarly identify a substantial autologous patient volume. Collection techniques, conditioning regimens and donor compatibility determine resource use.
Autologous Stem Cell TransplantsAutologous Stem Cell Transplants
Autologous grafts use the patient’s own harvested blood-forming progenitors, commonly after high-dose therapy for multiple myeloma or lymphoma. FDA-approved mobilization medicines include Aphexda and plerixafor. The absence of donor rejection simplifies matching, but patients still require apheresis, product testing and infection surveillance; residual cancer-cell contamination is a recognized clinical concern.
Allogeneic Stem Cell TransplantsAllogeneic Stem Cell Transplants
Donor-derived grafts account for substantial acute leukaemia and myelodysplasia treatment. EBMT recorded 21,023 allogeneic HCTs in 2024, and cord-blood products such as Omisirge create distinct acquisition and processing needs. Donor matching, graft-versus-host disease prevention and prolonged follow-up raise the complexity of each treatment episode.
Syngeneic Stem Cell TransplantsSyngeneic Stem Cell Transplants
Identical-twin grafts are uncommon because suitable donors are rare. NCI identifies syngeneic transplantation as a distinct donor relationship, but availability is constrained by family structure rather than procurement investment. Transplant centres still perform conditioning, cell collection and recovery monitoring, while the overall segment remains a small component of activity.
OthersOthers
This publisher category includes cord-blood processing and research-stage CSC-directed cell approaches not covered by the three transplant donor relationships. Omisirge provides a clear regulated example of manipulated cord blood used in a defined oncology transplant pathway; investigational CSC drug and cell research is not equivalent to approved transplant therapy.
Autologous volume is sensitive to clinical alternatives and the number of successful collections per patient, while allogeneic spending depends more heavily on donor search, graft processing and complications. Research-only CSC products are not counted as additional transplant procedures.
Cancer Stem Cell Therapy Market Segmentation by Application
Report SegmentationBy Application
Hospital represented an estimated ~73% of 2025 revenue because transplant conditioning, cell infusion and early complication management require specialized inpatient facilities. NCI identifies immune recovery as a multimonth process, reinforcing the role of transplant teams. The remaining settings participate through preparative care, follow-up and experimental laboratory work.
HospitalHospital
Accredited hospitals host collection coordination, chemotherapy conditioning, donor or autologous graft infusion and immediate recovery care. FDA-authorized cord-blood transplantation products enter an inpatient clinical pathway rather than a standard retail pharmacy channel. Graft-versus-host disease management and infection prevention generate additional resource demands around allogeneic care.
ClinicClinic
Specialty haematology clinics screen referrals, administer some pre-transplant treatments and coordinate follow-up. NHS England contracts blood and marrow transplantation through defined clinical commissioning arrangements, which place inpatient procedures in specialized centres while outpatient appointments support the longer pathway. Clinic activity therefore depends on hospital referrals and commissioning requirements.
Medical Research InstitutionMedical Research Institution
Universities and oncology institutes undertake CSC marker discovery, three-dimensional tumour cultures and small clinical studies. A 2024 review described CD44, CD133, ALDH and Wnt signalling as candidate research targets rather than universally validated clinical tests. Specialized culture media, flow cytometry and sequencing services form this category’s purchasing base.
OthersOthers
Other applications cover centralized processing hubs, donor registries and contracted support services associated with cancer-related grafts. Canadian Blood Services connects national donors with international matching systems. Commercial value derives from qualified collection, testing and supply rather than unsupervised use of investigational tumour-stem-cell preparations.
Hospital-linked purchases respond chiefly to the number and complexity of recognized transplant indications, whereas research-institution demand changes with funded projects and technical reproducibility. Combining the categories across classification axes would overstate total revenue.
Cancer Stem Cell Therapy Market Segmentation by End User
Report SegmentationBy End User
Healthcare Providers are the largest purchasing group because recognized HSC transplantation is delivered by hospitals and specialist teams. Academic & Research Institutes consume dedicated assays and models, while Pharmaceutical & Biotechnology Companies contract cell production and pursue investigational CSC-directed assets. Regulated transplant hospitals purchase clinically validated products, while oncology research institutes fund experimental marker assays.
Healthcare ProvidersHealthcare Providers
Transplant units purchase collection kits, mobilization medicines, graft products and clinical testing. HRSA lists 22,579 U.S. autologous and allogeneic marrow or cord-blood procedures for 2024; not every episode includes an expensive proprietary graft. Volume and hospital contracts drive provider purchases, and complications influence the fully treated cost.
Academic & Research InstitutesAcademic & Research Institutes
Academic laboratories investigate CSC plasticity, biomarker expression and resistance after cytotoxic therapy. STEMCELL Technologies provides cancer organoid and tumoursphere media, while Bio-Techne supplies progenitor-cell assay products. Purchases rely on research budgets, grant cycles and reproducibility requirements rather than approval of a therapy for clinical use.
Pharmaceutical & Biotechnology CompaniesPharmaceutical & Biotechnology Companies
Cell and drug developers use outsourced GMP services, analytic characterization and clinical testing for oncology cell-based programmes. Lonza reported new commercial cell-and-gene manufacturing contracts in its 2025 annual report. Contract work may involve supportive transplant products or experimental CSC-targeted programmes and should not be interpreted as approved CSC-drug sales.
Hospital budgets depend on national transplant reimbursement rules and access to specialized beds. Research laboratory purchasing is more closely linked to grants and assay platforms; manufacturers face milestone-based costs for clinical validation, product release and regulated production. Independent end-user shares represent the same total market, not separate additive markets.
Cancer Stem Cell Therapy Market Segmentation by Therapeutic Target
Report SegmentationBy Therapeutic Target
Hematological Cancers account for the largest established treatment revenue because blood and marrow transplant procedures are used for myeloma, leukaemia and lymphoma. NCI also identifies selected childhood solid tumours for transplantation. CSC-directed solid-tumour agents remain more experimental, so research activity should not be confused with routine cancer-treatment revenue.
Solid TumorsSolid Tumors
Neuroblastoma, germ-cell malignancies and selected relapsed paediatric tumours may involve high-dose chemotherapy followed by haematopoietic rescue under specific protocols. Research into breast, colorectal and pancreatic CSC signalling uses organoids and pathway assays, but 2025 peer-reviewed reviews describe inconsistent clinical results for many CSC-selective agents.
Hematological CancersHematological Cancers
Multiple myeloma and lymphomas support substantial autologous graft use, while acute leukaemias and myelodysplastic disorders support allogeneic procedures. EBMT data for 2024 place plasma-cell disorders at 59% of autologous HCT indications and myeloid malignancies at 62% of allogeneic indications. EBMT reports routine collection and transplantation for these indications, requiring qualified processing and longitudinal surveillance.
Other CancersOther Cancers
The publisher’s residual target category includes uncommon malignancies and early translational programmes without distinct routine transplant pathways. Clinical investigation may require biopsies, biomarker-based enrolment or experimental treatment combinations. Revenue is limited to identifiable research, contracted development and appropriate services; unapproved anticancer agents are not counted as standard care.
Disease eligibility is governed by clinical evidence, donor and patient characteristics, and available alternatives. Growth in experimental CSC platforms can widen research spending without establishing therapeutic efficacy or substituting for regulated transplant practice.
Cancer Stem Cell Therapy Market Regional Analysis
Region-specific demand reflects transplant-centre access, donor registries, payer eligibility and the supply of apheresis and graft-processing technologies. EBMT and national registries document procedural activity, but those counts are not used as proxies for country revenue. Research spending depends on oncology institutes and licensed laboratory capabilities.
North America
Largest market - ~42% of 2025 revenue
North America represented an estimated ~42% of 2025 revenue because U.S. transplant programmes combine high-acuity inpatient services with substantial cell collection, donor matching and procurement costs. The 2024 HRSA tabulation comprises 12,177 autologous and 10,402 allogeneic transplant procedures, reflecting a mix of autologous and related or unrelated allogeneic routes. FDA approval of Omisirge and Aphexda added transplant-associated drug and graft options, while Mesoblast Ryoncil addresses selected paediatric cases of graft-versus-host disease after allogeneic transplantation. The commercial pathway is therefore linked to specialized haematology centres and coverage policies, not broadly available cancer-stem-cell-directed cures. Canada contributes through donor matching and sophisticated hospital networks, although cross-border cell searches and follow-up planning can constrain throughput. The region also hosts translational programmes investigating CSC resistance and tumour organoids, which purchase research consumables independently of transplantation reimbursement.
Priority country signals
United States
Selected market signal
HRSA reports 12,177 autologous, 3,756 related allogeneic and 6,646 unrelated allogeneic marrow or cord-blood transplants in 2024. Those categories support demand for mobilization, collection disposables, processing and inpatient monitoring. FDA-authorized Omisirge and Aphexda apply only to their labelled indications, so technology adoption remains subject to hospital review, specialist referral and patient selection.
Source: HRSA transplant statistics.
Canada
Selected market signal
Canadian Blood Services reports a national registry connected with international stem-cell donor matching; Qu - bec maintains its own registration route through H - ma-Qu - bec. Availability of a compatible unrelated donor influences when allogeneic procedures can proceed and whether grafts cross borders. Investment in registry diversity and transplant coordination can support specialist hospital demand without creating an approved CSC-specific drug market.
Source: Canadian Blood Services.
Europe
Second-largest region - Mature transplant infrastructure
Europe is a major source of haematopoietic transplantation volume, hospital specialization and donor-registry participation. The EBMT counted 47,204 HCT procedures in its 2024 survey, drawn from European centres and collaborating countries, and recorded more allogeneic but fewer autologous procedures than in the preceding year. These numbers reflect cell-based interventions across several indications, not revenues from a selectively approved CSC medicine. National funding criteria shape procedure availability: NHS England commissions haematopoietic transplantation for specific conditions and age groups, while reimbursement differs among other European health systems. Germany and the United Kingdom support established collection and tissue-typing networks. Inpatient staffing, isolation facilities, transplant complications and graft testing account for significant service expenditure. Academic oncology groups in the region also investigate CSC-associated resistance using organoids and molecular targets; manufacturers require validated procurement pathways to convert laboratory discovery into regulated products.
Priority country signals
United Kingdom
Selected market signal
In September 2025, NHS England refreshed the clinical commissioning criteria for haematopoietic transplantation across all ages. Eligibility applies to specified diagnoses and patient subgroups, not to every experimental CSC-directed treatment. The framework supports funded hospital procedures while differentiating routine services from research trials. UK access to matched donor grafts and specialist bed capacity shapes procurement of consumables, apheresis services and follow-up.
Source: NHS England commissioning policy.
Germany
Selected market signal
EBMT’s 2024 activity survey records Germany among European countries with a high allogeneic transplant rate, reflecting established haematology centres and use of unrelated donors. Transplant capacity sustains purchases of graft-processing systems, donor-search services and laboratory products. Uptake of an investigational CSC-targeted compound would still require its own clinical evidence, regulatory authorization and reimbursement assessment.
Source: EBMT activity survey.
Asia-Pacific
Expansion opportunity - China and Japan registry capacity
Asia-Pacific transplant activity benefits from expanded hospital capacity, clinical training and domestic cell-processing research. The Chinese Blood and Marrow Transplantation Registry reported 21,714 HSC transplants for 2023, with allogeneic procedures accounting for a larger share than in several Western registries. Japan publishes a nationwide survey of haematopoietic transplantation and cellular therapy, including activity data for 2024, supporting more systematic procedure tracking. India coordinates transplant reporting through the Indian Society for Blood and Marrow Transplantation and is expanding multicentre outcome analysis. Regional cost differences influence access to matched donors, isolation capacity and supportive medicines. Chinese and Japanese researchers study immune and stemness mechanisms in cancer, yet approval of a biological therapy or regenerative product for another condition does not establish a market for clinically proven CSC ablation. Rising participation by research institutions increases consumption of specialist assays and culture media as clinical translation advances.
Priority country signals
China
Selected market signal
The Chinese Blood and Marrow Transplantation Registry documented 21,714 HSC transplants in 2023, including more than 15,000 allogeneic procedures and participation from 212 transplant teams. These findings distinguish China’s donor-intensive service requirements from Western autologous patterns. Domestic capacity and hospital investment support graft-processing and matching demand, although registry procedure counts do not reveal manufacturers’ CSC-specific pharmaceutical revenue.
Source: Chinese transplantation registry.
Japan
Selected market signal
The Japanese Data Center for Hematopoietic Cell Transplantation published its 2025 national survey report with transplant and cell-therapy counts, including 2024 activity tables. Standardized registry information permits comparison of procedure types and therapeutic indications across Japan. Specialist centres need validated collection and release systems; investigational tumour-stem-cell interventions remain governed separately by clinical-study and product authorization requirements.
Source: Japanese HCT Data Center.
India
Selected market signal
India’s national blood-and-marrow transplantation society maintains registry records for procedures and follow-up. A multicentre analysis of adult acute lymphoblastic leukaemia included 21 Indian transplant centres and recipients treated through June 2024. Tracking donor types and survival informs procurement and procedure standardization, while cost barriers and specialist availability continue to limit access to complex allogeneic programmes.
Source: Indian transplant study.
Latin America
Developing market - Registry-led capacity investment
Latin American demand is concentrated in specialized oncology and transplant hospitals, with Brazil providing a substantial evidence base for regional clinical activity. Public coverage, donor availability and laboratory capacity shape whether patients receive allogeneic or autologous treatment. Brazilian centres have expanded structured data reporting through collaboration between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation and the CIBMTR. Reporting improvement makes follow-up and transplant complications more visible, but published registry totals include treatments beyond oncology and do not establish regional manufacturer revenue. Medical centres use imported apheresis devices, cell-processing disposables and conditioning products; delivery cost includes inpatient monitoring and infection prevention. Academic groups can investigate CSC biology, but unapproved pathway inhibitors do not constitute a routinely reimbursed regional therapy class. Inflation, foreign-exchange movements and reimbursement constraints can slow procurement even when centre demand grows. Brazilian registry expansion also increases requirements for trained data managers and standardized transplant follow-up across public centres, rather than creating separate pharmaceutical revenue.
Priority country signals
Brazil
Selected market signal
A 2025 Brazilian registry analysis reported growth from 11 to 32 centres actively submitting data to CIBMTR between 2016 and 2024, with reported HCT cases rising from 628 to 1,909. CIBMTR-linked Brazilian case reporting provides centres with outcome data for benchmarking and follow-up. It does not independently establish Brazilian CSC-drug revenue, but it documents an expanding infrastructure for collecting, tracking and managing oncology-related transplantation.
Source: Brazilian HCT registry study.
Middle East & Africa
Emerging care centres - Access shaped by transplant specialization
Middle East and African markets contain a small number of highly specialized programmes, with more developed transplant capability in parts of the Gulf and uneven capacity elsewhere. A Saudi Society of Blood and Marrow Transplantation survey recorded active graft services, donor registries and cord-blood banks, highlighting the role of national infrastructure in serving patients with blood malignancies. EBMT’s 2024 survey also included collaborating centres in several Middle Eastern and African countries, but aggregate data cannot determine the region’s manufacturing revenue. Selected tertiary hospitals in the United Arab Emirates provide marrow transplantation for patients with multiple myeloma and other blood disorders. Specialist staffing, donor matching and laboratory accreditation govern expansion more strongly than the number of CSC research projects. Cross-border referrals may be necessary where complex allogeneic procedures are unavailable. Research activity will generate limited specialist reagent demand before any CSC-selective agent demonstrates sufficient evidence for routine oncology treatment.
Priority country signals
Saudi Arabia
Selected market signal
A national transplant activity survey published in March 2024 recorded two donor registries, two cord-blood banks and more than 160,000 registered donors. Acute myeloid leukaemia and lymphoid neoplasms were major allogeneic transplant indications. These infrastructures support collection, storage and clinical services, while access to matched grafts and specialised infection control remains central to patient eligibility.
Source: Saudi transplantation survey.
United Arab Emirates
Selected market signal
Cleveland Clinic Abu Dhabi documented a multiple-myeloma patient receiving marrow transplantation in August 2023, establishing that highly specialized treatment is available within the country. Such programmes need transplant teams, clinical laboratory support and follow-up capabilities. A hospital case study does not represent national procedure volume, and it does not demonstrate authorization of a medicine that selectively targets cancer stem cells.
Source: Cleveland Clinic Abu Dhabi.
Transplant Pricing, Reimbursement & Market Access
Access to oncology-related HSC transplantation is determined by diagnostic eligibility, donor availability, hospital accreditation and national reimbursement arrangements. Price comparisons between approved graft products and investigational CSC inhibitors are inappropriate because their clinical indications and regulatory statuses differ.
| Access System |
Verified Policy or Event |
Commercial Consequence |
| United States |
FDA approvals for Omisirge, Aphexda and Ryoncil, 2023–2024 |
Product use subject to label, physician selection and payer review |
| England |
NHS HSCT commissioning policy, updated September 2025 |
Eligibility defined by condition and clinical subgroup |
| Canada |
National donor registry linked with international matching |
Graft search and matching affect time and service costs |
| Europe |
EBMT 2024 registry: 47,204 HCT procedures |
Specialized centres and donor networks underpin procurement |
| Saudi Arabia |
National donor registries and cord-blood banks |
Collection and transplant infrastructure supports access |
In the United States, HRSA documented 22,579 marrow and cord-blood transplant procedures in 2024. Autologous procedures require mobilization and apheresis, while allogeneic procedures add donor and graft-compatibility activities. FDA-approved Aphexda is a mobilization medicine, Omisirge is a manipulated cord-blood graft, and Ryoncil treats steroid-refractory graft-versus-host disease in specific paediatric patients. Reimbursement for each product depends on a different diagnosis, hospital pathway and clinical benefit, preventing direct price substitution between them.
NHS England funds haematopoietic transplantation for defined disorders and patient subgroups under its clinical commissioning policy, updated in September 2025. The September 2025 NHS policy identifies reimbursed transplant indications rather than authorizing novel CSC-directed medicines. Canadian Blood Services relies on international registries to help match donors, making transportation, tissue typing and timing relevant to procedure cost. The absence of a matched donor can delay an allogeneic transplant despite hospital capacity, while autologous collection depends on a sufficient harvested progenitor-cell dose.
EBMT’s 2024 survey reported a reduction in autologous HCT procedures and an increase in allogeneic procedures relative to 2023. Procedure mix shifts purchases between mobilization drugs, donor-search services and infection or graft-versus-host disease management. Experimental CSC pathway inhibitors have no blanket transplant reimbursement: developers need separately persuasive patient selection, efficacy and safety findings before government health systems can consider coverage. Spending on organoid models or tumor-marker assays is financed through laboratory and research budgets instead of patient drug benefits.
Source: NHS England; HRSA; FDA Omisirge.
Stem Cell Product Regulation & Cancer Stem Cell Pipeline
FDA product authorization covers narrow transplant-related indications, while CSC-selective pathway and immune therapies generally remain investigational. Regulatory assessment is driven by patient eligibility, manufacturing consistency, adverse events and evidence of benefit in controlled clinical studies.
| Date |
Regulatory or Research Milestone |
Verified Scope |
Commercial Relevance |
| Apr 2023 |
FDA approves Omisirge |
Blood malignancies undergoing cord blood transplantation |
Commercial manipulated-graft route |
| Sep 2023 |
FDA approves Aphexda |
Autologous myeloma stem-cell mobilization |
Alternative collection workflow |
| Sep 2024 |
China HCT registry analysis published |
21,714 transplants in 2023 |
Evidence for service capacity |
| Dec 2024 |
FDA approves Ryoncil |
Paediatric steroid-refractory acute GVHD |
Supportive treatment following allo-HCT |
| Dec 2025 |
FDA expands Omisirge label |
Severe aplastic anaemia, a non-cancer indication |
Broader product manufacturing scope |
| May 2026 |
EBMT publishes 2024 activity survey |
47,204 HCT procedures reported |
Clinical volume and indication data |
On 17 April 2023, FDA authorized omidubicel-onlv to shorten neutrophil recovery and reduce infections after cord-blood transplantation for specific patients with haematological malignancies. The approval does not establish efficacy against CSCs in solid tumours. Aphexda entered the U.S. market in September 2023 for mobilization in multiple myeloma, and Ryoncil received approval in December 2024 for steroid-refractory acute GVHD after transplantation. These products occupy different procedure stages and cannot be aggregated as equivalent antitumour medicines.
FDA subsequently expanded Omisirge’s indication in December 2025 to include severe aplastic anaemia after reduced-intensity conditioning. That is a nonmalignant indication and should not be added to oncology-only revenue. Separately, investigators continue to examine Wnt, Hedgehog, Notch, PI3K and metabolic vulnerabilities in malignant stem-like cells. Peer-reviewed assessments in 2024 and 2025 document toxicity, pathway redundancy and resistant-cell plasticity as major obstacles to a broadly effective CSC-specific therapy.
Developers pursuing CSC-selective agents must demonstrate benefit in defined populations rather than rely only on reduced cancer-stem-cell marker expression. Tumour organoids, immune profiling and validated cell-characterization assays can support preclinical selection, but clinical endpoints such as recurrence, survival and treatment-related harm remain decisive. Manufacturing firms supplying collection and HSC expansion tools have established regulated customer demand; companies pursuing CSC-specific drugs face separate clinical, regulatory and payer milestones before therapeutic revenue is routine.
Competitive Landscape
Commercial participants occupy distinct stages of the oncology stem-cell pathway: FDA-authorized grafts and mobilization drugs, transplant-related supportive care, apheresis devices, cell manufacturing and experimental CSC assays. Competition is fragmented because buyers of hospital collection equipment are not interchangeable with developers of investigational antitumour drugs.
Approved grafts and mobilizationGamida Cell, BioLineRx, Sanofi
Gamida Cell markets Omisirge for specified transplantation indications, while BioLineRx developed Aphexda for mobilization in multiple myeloma. Sanofi’s legacy Mozobil (plerixafor) is an established mobilisation option for autologous graft collection. FDA documentation distinguishes those approvals from investigational CSC eradication. Hospital formularies and collection performance affect uptake and supplier selection.
Collection and processing equipmentFresenius Kabi, Terumo BCT, Miltenyi Biotec
Fresenius Kabi’s Amicus platform supports mononuclear-cell harvesting, while Terumo BCT’s Spectra Optia handles therapeutic apheresis and marrow processing. Miltenyi Biotec supplies CliniMACS systems for CD34-positive cell processing. Buyers compare throughput, contamination control, disposables, training and validated workflows rather than unproven tumor-stem-cell outcomes.
Research tools and assaysThermo Fisher, Bio-Techne, STEMCELL Technologies
Thermo Fisher CTS StemPro media support culture of normal haematopoietic progenitors; Bio-Techne offers CD34 progenitor colony-forming assays. STEMCELL Technologies markets products for tumor organoids and tumoursphere biology. These vendors participate through laboratory reagents and cell models used in oncology discovery, not sales of authorized CSC-directed anticancer pharmaceuticals.
GMP and transplantation supportLonza and Mesoblast
The Lonza 2025 annual report described newly contracted programmes for commercial cell and gene manufacturing, illustrating contracted production economics. Mesoblast’s Ryoncil received FDA approval in December 2024 for severe paediatric graft-versus-host disease after allogeneic transplantation. Both serve clinically adjacent markets with different revenue boundaries and regulatory requirements than direct CSC elimination.
Collection equipment vendors generally serve established recurring procedure demand because each autologous or allogeneic episode requires qualified instruments and single-use supplies. Research suppliers instead respond to biomarker validation, grant funding and the development of organoid or progenitor cell models. Lonza’s contracted GMP programmes highlight the importance of process validation and batch release, particularly when a manufacturer pursues clinical cell products with controlled identity and potency.
Gamida Cell, BioLineRx and Mesoblast rely on product-specific clinical indications, with FDA labels constraining patient eligibility. Syngeneic transplantation remains very limited, and investigational CSC therapies face additional proof requirements. Competitive strategy therefore involves collection efficiency, acceptable patient risk, donor access, scientific differentiation and cost to serve rather than market-share ranking across dissimilar products. Larger oncology drug makers without clearly verified in-scope products have been excluded.
Key Companies Profiled
- Gamida Cell Ltd.
- BioLineRx Ltd.
- Mesoblast Limited
- Sanofi S.A.
- Fresenius Kabi AG
- Terumo Blood and Cell Technologies
- Miltenyi Biotec
- Thermo Fisher Scientific Inc.
- Bio-Techne Corporation
- STEMCELL Technologies Inc.
- Lonza Group AG
Recent Developments in the Cancer Stem Cell Therapy Market
May 2026: The EBMT published its 2024 activity report on 27 May 2026, describing 47,204 HCT procedures across 53 reporting countries and 6,082 CAR-T recipients. Autologous HCT declined while allogeneic activity grew compared with 2023. These data inform transplant supply planning and reveal changes in donor-related procurement, but the registry does not classify routine grafts as dedicated CSC-elimination medicines. Source
December 2025: The FDA expanded Omisirge to patients aged six and older with severe aplastic anaemia after reduced-intensity conditioning. The indication is non-oncological and must be excluded from cancer-specific revenue despite using the same manufactured cord-blood cell product. The label expansion demonstrates that commercial graft suppliers can serve several indications while transplant-related oncology spending follows separate patient eligibility rules. Source
September 2025: NHS England updated its all-ages haematopoietic stem-cell transplantation commissioning policy on 2 September 2025. The policy identifies clinical conditions and subgroups for commissioned treatment, distinguishing recognized practice from experimental CSC pathway inhibition. Contracted hospital access therefore depends on established evidence and eligibility rather than laboratory markers alone. Source
December 2024: The FDA approved Ryoncil (remestemcel-L-rknd) on 18 December 2024 for paediatric patients with steroid-refractory acute graft-versus-host disease following allogeneic transplantation. In the supporting 54-patient study, 30% achieved complete response and 41% partial response by day 28. This supportive-care authorization does not constitute an approval for direct cancer-stem-cell eradication. Source
September 2024: A Chinese Blood and Marrow Transplantation Registry analysis published on 25 September 2024 documented 21,714 HSC transplant procedures during 2023, including more than 15,000 allogeneic cases. Participation from 212 teams indicates substantial donor-intensive service activity. National procedure reporting supports country-specific capacity analysis without justifying a derived estimate of CSC-specific drug sales. Source
September 2023: The FDA approved Aphexda (motixafortide) on 8 September 2023 for use with filgrastim to mobilize progenitor cells before autologous transplantation in multiple myeloma. The clinical evaluation enrolled 122 patients, including 78 at U.S. sites. The approval provides a distinct collection-related drug option, although it does not authorize selective treatment of tumour-initiating cancer stem cells. Source
Market Outlook, 2026–2034
Cancer-related stem-cell procedure, product and research revenue is forecast to increase from USD 1.39 billion in 2026 to USD 3.54 billion in 2034, consistent with a 12.4% CAGR across the eight forecast intervals. Established transplant demand and investigational CSC technologies have different adoption pathways.
| Forecast Driver |
Evidence-Based Starting Point |
Likely Commercial Effect |
| Patient need |
20.6M global cancer diagnoses, 2024 |
Persistent oncology infrastructure demand |
| Transplant volumes |
47,204 HCT procedures in EBMT 2024 survey |
Recurring graft, monitoring and collection needs |
| Autologous mobilization |
FDA Aphexda approval in 2023 |
Collection drug and service competition |
| Manipulated cord blood |
Omisirge authorized for defined patients |
Commercial product pricing linked to eligibility |
| CSC research |
2025 review of Wnt/Notch/Hedgehog and immune strategies |
Investigational contracts with clinical risk |
| Geographic capacity |
China registry: 21,714 HCTs in 2023 |
Procedure and laboratory expansion in Asia |
Future treatment volumes will depend on transplant indications, patient fitness, competing therapies and the availability of suitable donor grafts. EBMT’s 2024 registry documented a 2.6% increase in allogeneic procedures alongside a 3.9% decrease in autologous procedures, illustrating that cell-therapy adoption does not expand uniformly. Autologous collection and myeloma-related activity support apheresis and mobilization purchases, whereas allogeneic services require matching, graft processing and a longer immune-recovery period. Hospitals may therefore grow revenue per episode through complexity even when procedure counts are flat.
FDA approvals for Omisirge, Aphexda and Ryoncil provide specific regulated product channels but no universal licence for cancer-stem-cell eradication. Omisirge’s December 2025 expansion into severe aplastic anaemia illustrates the need to exclude non-cancer indications from an oncology revenue boundary. Research laboratories will continue to purchase progenitor characterization reagents, tumoursphere culture systems and molecular readouts as they study CSC heterogeneity, but such sales are not equivalent to an approved therapy for metastatic solid tumours.
North America should retain a high-value position through specialized transplant hospitals and access to FDA-authorized products. Europe benefits from established EBMT networks and national commissioning programmes, while China and Japan document increasing visibility of transplant activity through registries. Brazil and Saudi Arabia provide evidence of developing national collection and outcome-tracking infrastructure. Higher care intensity, payer constraints and shortages of specialist staff may prevent procedure growth from following cancer-incidence increases one-for-one.
The largest commercial risks concern graft-related mortality, infection, payer restrictions, donor access and replacement of some transplants by better tolerated therapies. CSC-targeted candidates also face pathway redundancy, toxicity and a need for predictive biomarkers, as documented in peer-reviewed reviews. Upside would require randomized evidence of longer remission or survival in appropriately selected patients, followed by authorization and funding. Until that occurs, forecast value rests predominantly on established transplant workflows and directly attributable supporting services rather than speculative CSC drug sales.
Report Coverage
Coverage tracks oncology-related HSC transplantation and directly associated materials, services and investigational CSC research across the defined 2025–2034 revenue framework.
Market Forecast2025 base, 2026 estimate, 2034 forecast and 2026–2034 annual growth.
Four DimensionsType, Application, End User and Therapeutic Target with publisher categories.
Geographic FootprintFive regions with country evidence for hospital capacity, policy and registries.
Treatment BoundaryDistinction between HSC replacement and investigational cancer-stem-cell targeting.
Competitive SupplyAuthorized mobilization, graft, supportive therapy, collection devices and research reagents.
Clinical & Policy SignalsFDA labels, national commissioning, transplant registries and CSC biomarker research.
Frequently Asked Questions
How big is the Cancer Stem Cell Therapy Market?
The defined global cancer stem cell therapy market accounted for **USD 1.24 billion in 2025** and is estimated at USD 1.39 billion for 2026. This scope includes eligible oncology transplant services and related cell-processing and research activities; it is not a measured total of approved drugs designed to eradicate tumour-initiating cells.
What is the CAGR for the Cancer Stem Cell Therapy Market through 2034?
The forecast annual growth rate is **12.4% from 2026 to 2034**, taking the modeled revenue pool to USD 3.54 billion by the final year. Procedure access, donor matching, hospital purchasing and targeted research investment underpin that projection; experimental CSC-drug approvals remain a separate uncertainty.
Are any cancer stem cell therapies approved by the FDA?
No broadly approved FDA medicine is labeled to eradicate cancer stem cells as a distinct tumour subpopulation. FDA-approved Omisirge supports specific cord-blood transplants for blood cancers, and Aphexda assists stem-cell mobilization before autologous myeloma transplantation. Their regulated uses do not demonstrate direct CSC elimination.
What is the difference between autologous and allogeneic stem cell therapy for cancer?
Autologous transplantation uses a patient’s own blood-forming stem cells, whereas allogeneic transplantation uses a donor graft. NCI identifies different complications and eligibility requirements for the two routes. Autologous collection avoids donor graft-versus-host disease, while allogeneic procedures require compatibility matching and prolonged immune monitoring.
Which region leads the Cancer Stem Cell Therapy Market?
North America is the largest regional market, representing an estimated **~42% of 2025 revenue** for the defined procedures and supporting products. HRSA reported 22,579 blood- and marrow-cell transplant procedures across the United States in 2024, while FDA-authorized graft and collection products support specialist hospital purchasing.
Does insurance or the NHS cover stem cell transplantation for cancer?
Coverage is available for qualifying haematopoietic stem-cell transplant indications, not for every experimental CSC-targeting treatment. NHS England’s commissioning policy specifies supported diagnoses and patient subgroups, while U.S. reimbursement depends on payer and care-setting rules. Patients need specialist assessment of transplant eligibility, donor options and treatment-related risks.
Is Omisirge more effective than a standard cord blood transplant?
Omisirge produced faster median neutrophil recovery in its supporting study, at 12 days versus 22 days with conventional cord blood, and fewer serious infections by day 100. Those results concern defined transplant endpoints and do not establish superiority against all cancers or selective activity against tumour-initiating cancer stem cells.
Which companies develop or supply cancer-related stem cell treatments?
Gamida Cell supplies Omisirge, BioLineRx developed Aphexda, and Mesoblast markets a transplant-complication treatment. Fresenius Kabi, Terumo BCT and Miltenyi Biotec offer collection or processing technologies. Thermo Fisher, Bio-Techne, STEMCELL Technologies and Lonza participate through cell culture, assay products or contracted manufacturing.
Why are cancer stem cells hard to target with medicines?
Cancer stem cells can change phenotype and activate overlapping Wnt, Notch, Hedgehog and metabolic pathways. A 2025 scientific review documented pathway compensation, off-target toxicity and variable clinical responses. These challenges make tumour-marker confirmation, controlled trials and clinically meaningful survival endpoints necessary before broad treatment authorization.
Are there generic alternatives to stem cell transplant medicines?
Mobilization pathways include established plerixafor options such as Mozobil and newer Aphexda, but product selection depends on the approved indication and collection requirements. There is no generic counterpart to an unapproved CSC-selective therapy. Manipulated cord-blood grafts and laboratory reagents also differ from interchangeable small-molecule medicines.
Who receives cancer stem cell-related transplantation treatments?
Eligible patients are most often people with blood cancers such as multiple myeloma, lymphoma or leukaemia, depending on transplant type and clinical condition. NCI also lists selected paediatric solid-tumour applications. Donor availability, disease stage, previous therapy and tolerance for high-dose treatment influence the decision.
What is the future outlook for CSC-targeted cancer therapies?
Clinical research will continue testing cancer stem-cell pathways and immune combinations, while authorized transplantation remains concentrated in selected malignancies. The 2034 market forecast reflects oncology-associated procedure and technology spending rather than presumed approval of an experimental CSC drug. Better patient-selection biomarkers and trial outcomes would be needed for material therapeutic revenue.
Research Sources & Evidence Base
View research sources used for this overview
- IARC. Global cancer statistics 2024: 20.6 million new cancer cases, July 2026.
- National Cancer Institute. Stem Cell Transplants in Cancer Treatment.
- HRSA. Blood Stem Cell Transplant Program: frequently asked questions and 2024 activity.
- EBMT / Bone Marrow Transplantation. 2024 activity report: one million HCTs, May 2026.
- FDA. Approval of Omisirge for blood cancers and cord-blood transplantation, April 2023.
- FDA. APHEXDA clinical trial snapshot and approval, September 2023.
- FDA. Ryoncil approved for steroid-refractory acute graft-versus-host disease, December 2024.
- FDA. Omisirge approvals and indication history, December 2025.
- Chinese Blood and Marrow Transplantation Registry Group. HSC transplantation activity in China, 2022–2023, September 2024.
- Japanese Data Center for Hematopoietic Cell Transplantation. 2025 Annual Report of Nationwide Survey.
- Indian Society of Blood and Marrow Transplantation. Adult ALL allogeneic HSCT outcomes in India.
- Brazilian Registry of Hematopoietic Cell Transplantation. Registry development and activity, 2016–2024, October 2025.
- Saudi Society of Blood and Marrow Transplantation. Saudi transplant activity landscape survey, March 2024.
- Cleveland Clinic Abu Dhabi. Bone marrow transplant saves cancer patient, August 2023.
- NHS England. Clinical commissioning policy: HSCT all ages, September 2025.
- Canadian Blood Services. Donating Stem Cells and stem-cell registry programmes.
- Peer-reviewed review, PMC. Cancer stem cells: landscape, challenges and emerging therapeutic innovations, August 2025.
- Fresenius Kabi. Therapeutic apheresis and Amicus cell collection.
- Terumo Blood and Cell Technologies. Spectra Optia bone marrow processing protocol.
- Miltenyi Biotec. CliniMACS Prodigy hematopoietic stem cell engineering.
- Thermo Fisher Scientific. CTS StemPro HSC Expansion Medium product FAQ.
- Bio-Techne / R&D Systems. Human methylcellulose media for CD34-positive progenitors.
- STEMCELL Technologies. MammoCult for mammospheres and tumorspheres.
- Lonza. 2025 annual report: specialized modalities and commercial cell therapies.
- FDA. Mozobil (plerixafor) orphan-drug approval listing.